Ablexis, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, and AlivaMab Discovery Services (ADS), a contract research organization offering comprehensive antibody drug discovery services using the AlivaMab Mouse, together offer unparalleled capabilities for organizations of all sizes, from virtual to global biopharmas, to obtain lead candidate antibodies that meet target product profiles with both time and capital efficiency. The AlivaMab Mouse platform at the core of Ablexis’s and ADS’s offering is a transgenic mouse optimized for antibody drug discovery and development that delivers high-affinity, high-potency antibody candidates with better developability profiles and with faster timelines than other platforms on the market.
Ablexis offers multiple licensing structures and flexible licensing terms to accommodate organizations of all sizes. ADS provides exceptional capabilities in antibody drug discovery backed by decades of experience in therapeutic antibody generation, screening and functional assay development and execution, and recombinant antibodies.
"Successful, fast movement from discovery to clinical development is more important than ever in capturing value - Ablexis's AlivaMab Mouse technology brings quality, speed, and value in generating development-ready antibodies that meet target product profiles, making it the best-in-class platform for antibody drug discovery and development," said Larry Green, founder and CEO of Ablexis and ADS. "AlivaMab Mouse avoids the false economies of competing platforms - other transgenic, in vitro and humanization. For outsourcing therapeutic antibody discovery, ADS provides exceptional capabilities in antibody drug discovery using AlivaMab Mouse."
The AlivaMab Mouse advantage
The AlivaMab Mouse is uniquely designed for success and speed in antibody drug discovery and development. It produces chimeric human-mouse monoclonal antibodies comprising fully human Fab and upper hinge regions and mouse middle hinge and Fc regions. Optimized constant domains enable the rapid generation and idenitification of development candidates that retain critical structure-function characteristics (Fig. 1).
Antibodies from AlivaMab Mouse exhibit druglike biophysical properties that are predictive of and comparable to that of their fully human counterparts, which highly facilitates therapeutic candidate election. An optimized human V gene repertoire that incorporates select human VH, Vk and V genes and thoughtfully designed cis regulatory elements yields immune responses, high human complementarity determining region 3 (CDR3) molecular diversity and broad epitope coverage superior to any other transgenic animal platform available for licensing. Overall, the platform results in higher efficiency and probability of success through faster, more robust and more diverse immune responses, delivering therapeutic candidates that are chemistry, manufacturing and controls (CMC)-compliant and are derisked with regard to their potential immunogenicity in patients.
The AlivaMab Mouse platform is currently licensed by top pharmaceutical companies such as AbbVie, AstraZeneca, Boehringer Ingelheim, Janssen, Eli Lilly, Novartis, and Pfizer, and numerous other companies ranging in size from global biopharmaceutical companies to virtual operations. AlivaMab Mouse has been internalized by more than a dozen companies in North America, the European Union, and Asia and is used in a wide range of antibody discovery applications, evidencing its user-friendliness. Licensees may use AlivaMab Mouse in-house, at AlivaMab Discovery Services, or at other select service providers.
ADS: customized antibody development solutions
ADS, founded in 2018, delivers value through quality results and speed in antibody drug discovery. A seasoned team of scientists with decades of experience in the field at large and small companies has developed a fully integrated suite of services to provide clients with modular solutions across the entire workflow of antibody drug discovery, ranging from consulting on the target product profile, functional assay development, antigen design, and immunization through to the delivery of antibody leads for preclinical studies. The ADS team offers expertise and innovation in collaboration with each partner’s scientists to create customized project plans tailored to the target type, antibody design goals, and the needs of the client to deliver antibody candidates that meet or exceed project goals.
The company provides the necessary expertise to produce large panels of sequence and epitopediverse, high-affinity monoclonal antibodies against a broad variety of target types, including membrane multi-spanners and targets with high sequence conservation between mice and humans. ADS has developed an efficient and streamlined path to optimal functional leads built on the team’s expertise in efficiently generating therapeutic-quality antibodies against a variety of targets along with the functional assay design and execution to ensure that screening assays identify the better lead candidate antibodies earlier in the screening process. The years of experience in generating therapeutic-quality antibodies from rodents, both wild-type and transgenic, accumulated by ADS’s scientists allow the team to position a client’s discovery program for success while preempting and navigating through potential pitfalls and avoiding a one-size-fits-all approach to therapeutic antibody generation.